Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Omrix initiates Phase I/II trial of Adhexil
The study will evaluate the safety and initial efficacy of Adhexil in preventing and/or reducing post-operative adhesions in patients undergoing gynecological surgery of the ovaries. The clinical trial
The study will evaluate the safety and initial efficacy of Adhexil in preventing and/or reducing post-operative adhesions in patients undergoing gynecological surgery of the ovaries. The clinical trial
The shares of Optimer’s common stock to be sold in the private placement have not been registered under the Securities Act of 1933, as amended or state securities
The single ascending dose study is being conducted in the US under an exploratory investigational new drug application and will evaluate the safety and pharmacokinetics of three doses
In the Phase I study, R1507 was administered by intravenous infusion. Nine of 34 adult patients with advanced solid tumors experienced disease stabilization. Four of the seven heavily
BioSante’s board of directors has approved the decision to switch the listing of BioSante’s common stock from the American Stock Exchange to the Nasdaq stock global market. BioSante’s
As a result of approving this indication, Sigmart injection is considered to offer a new therapeutic option to patients who need intravenous administration of vasodilators. Sigmart injection is
The primary endpoint of the study is overall survival and time to objective disease progression is a secondary endpoint. The company currently expects an interim analysis for overall
The trial demonstrated objective evidence of efficacy in 10 of the 13 evaluable patients with advanced treatment-refractory tumors in the liver (primary and metastatic). Responses were particularly encouraging
Contrave employs a proprietary formulation of two CNS molecules, bupropion and naltrexone, that have been independently approved by the FDA in other indications. The unique combination of these
The Mexican Soluble Ferric Pyrophosphate (SFP) patent grant covers the method and pharmaceutical composition for iron delivery administered in hemodialysis and peritoneal dialysis patients. Based on previous FDA